Short answer
Emergent BioSolutions Inc. (EBS) filed its Q1 2026 10-Q quarterly report on May 1, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $156M (down 29.7% year over year) with net income of $7M.
Q1 2026 key financials · XBRL
- Revenue
- $156M
- −29.7% YoY
- Net income
- $7M
- −90.0% YoY
- Operating margin
- 6.7%
- EPS (diluted)
- $0.07
- −94.1% YoY
Source: XBRL data from the Emergent BioSolutions Inc. (EBS) Q1 2026 10-Q on SEC EDGAR. USD.
Emergent BioSolutions Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Third-party manufacturing dependence, including sole-source suppliers, threatens product availability and margins
- FDA noncompliance at contract manufacturers could force cessation of production and disrupt customer supply
- Political opposition and negative publicity may delay product launches or reduce U.S. government purchases
- Winnipeg production faces potential U.S.-made procurement preferences that could reduce government demand
- Reauthorized $50.0 million share repurchase program through March 31, 2027 may reduce liquidity flexibility
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Emergent BioSolutions Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.